CA2284483A1 - Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus - Google Patents

Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus Download PDF

Info

Publication number
CA2284483A1
CA2284483A1 CA002284483A CA2284483A CA2284483A1 CA 2284483 A1 CA2284483 A1 CA 2284483A1 CA 002284483 A CA002284483 A CA 002284483A CA 2284483 A CA2284483 A CA 2284483A CA 2284483 A1 CA2284483 A1 CA 2284483A1
Authority
CA
Canada
Prior art keywords
reverse transcriptase
ddi
hiv
transcriptase inhibitor
hydroxycarbamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284483A
Other languages
English (en)
Inventor
Jorge Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284483A1 publication Critical patent/CA2284483A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition s'utilisant comme un médicament, notamment pour inhiber la propagation d'un rétrovirus, la composition comprenant au moins deux inhibiteurs de transcriptase inverse différents et un hydroxycarbamide.
CA002284483A 1997-03-20 1997-03-20 Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus Abandoned CA2284483A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1997/000275 WO1998042349A1 (fr) 1997-03-20 1997-03-20 Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus

Publications (1)

Publication Number Publication Date
CA2284483A1 true CA2284483A1 (fr) 1998-10-01

Family

ID=11004539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284483A Abandoned CA2284483A1 (fr) 1997-03-20 1997-03-20 Melanges formes d'au moins deux inhibiteurs de transcriptase inverse et d'hydroxycarbamide, destines en particulier a inhiber une propagation de retrovirus

Country Status (5)

Country Link
EP (1) EP0971715A1 (fr)
JP (1) JP2001521548A (fr)
AU (1) AU743942B2 (fr)
CA (1) CA2284483A1 (fr)
WO (1) WO1998042349A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread

Also Published As

Publication number Publication date
AU743942B2 (en) 2002-02-07
JP2001521548A (ja) 2001-11-06
WO1998042349A1 (fr) 1998-10-01
EP0971715A1 (fr) 2000-01-19
AU2104697A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
US5736527A (en) Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5736526A (en) Mixtures of DDI and D4T with hydroxycarbamide for inhibiting retroviral replication
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
US5719132A (en) Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
JPS63107936A (ja) 後天性免疫不全症ａｉｄｓに対する医薬
US20080139496A1 (en) Combination therapy for reduction of toxicity of chemotherapeutic agents
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
Pereira et al. Anti-HIV drug development-an overview
Falcone et al. Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice
RU2203047C2 (ru) Композиция для снижения содержания церамидов
Romanelli et al. Hydroxyurea to inhibit human immunodeficiency virus‐1 replication
Connell et al. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor
AU743942B2 (en) Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
US6649644B1 (en) Method of treating HIV infection by combined use of a cytotoxic agent and a non-nucleoside reverse transcriptase inhibitor
EP0255420B1 (fr) Agent antiviral d&#39;inhibition de la croissance du virus du syndrome immuno-deficitaire acquis (SIDA)
US5541212A (en) Use of cimetidine for the control of retrovirus infections
Saag Adverse Effects
AU718325B2 (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
JPH0262533B2 (fr)
WO1995020388A1 (fr) Medicaments anti-vih
AU702469B2 (en) Composition and method of treating retroviral infection
WO1995017875A2 (fr) MELANGES DE DIDESOXY-NUCLEOSIDES ET DE β-HYDROXAMATE DE L&#39;ACIDE D-ASPARTIQUE UTILISE DANS L&#39;INHIBITION DE LA PROPAGATION D&#39;UN RETROVIRUS
Kahn The clinical use of didanosine
JPH08208502A (ja) 抗エイズウイルス剤の効果増強剤
JPH0616561A (ja) 抗レトロウイルス剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead